

09.30.2013

INTERIM REPORT

GROWTH & INNOVATION



PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

CONTENTS

- 03 HIGHLIGHTS/KEY GROUP FIGURES AT A GLANCE
- 04 FOREWORD BY THE BOARD OF MANAGEMENT
- 05 INTERIM GROUP MANAGEMENT REPORT
- 09 CONSOLIDATED BALANCE SHEET
as of September 30, 2013
- 11 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the Period from July 1 to September 30, 2013
- 12 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the Period from January 1 to September 30, 2013
- 13 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the Period from January 1 to September 30, 2013
- 15 CONSOLIDATED CASH FLOW STATEMENT
for the Period from January 1 to September 30, 2013
- 16 NOTES TO THE GROUP INTERIM REPORT
for the Period from January 1 to September 30, 2013
- 20 ADDITIONAL INFORMATION

HIGHLIGHTS

Sales of €90.4 million in 9M/2013
(+7.2%; 9M/2012: €84.3 million*)

EBIT margin of 16.2% in Q3/2013
(Q3/2012: 13.4%)

EBIT margin of 14.8% in 9M/2013
(9M/2012: 15.8%*)

Earnings per share of €0.90 in 9M/2013
(-3.2%; 9M/2012: €0.93)

Company forecast confirmed

KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01. – 09.30.2013	01.01. – 09.30.2012	Change
Sales	90,418	84,316*	+7.2%
EBIT	13,361	13,357	+0.0%
EBIT margin (%)	14.8	15.8*	-
Consolidated net income	10,517	10,865	-3.2%
Earnings per share (€)	0.90	0.93	-3.2%
No. of employees (absolute)	544	524	+3.8%

in € thousands	09.30.2013	12.31.2012	Change
Shareholders' equity	95,874	91,985	+4.2%
Total assets	127,341	121,838	+4.5%
Equity ratio (%)	75.3	75.5	-

* 2012 figure adjusted for a one-off item of €3.3 million due to an income-neutral reclassification from unfinished services and prepayments received upon the write-down of a development project. On an unadjusted basis, sales for the first nine months of 2012 amounted to €87.6 million and the corresponding EBIT margin amounted to 15.3%.

FOREWORD BY THE BOARD OF MANAGEMENT

Dear Shareholders,

We can now look back on the first nine months of the 2013 financial year. Notwithstanding uncertainties within the diagnostics industry as to spending cuts in the global healthcare system, business with our partners is still developing positively after the first nine months.

We increased our sales year-on-year by 3.2% to €90.4 million in the first nine months of 2013. Net of a one-off, non-operating item in the first quarter of the previous year, our sales showed growth of 7.2%. At 14.8%, our nine-month EBIT margin was also within the range of 14.0% to 15.5% budgeted for the overall financial year. In the third quarter, our year-on-year sales growth amounted to 5.8% to €31.0 million, with an EBIT margin of 16.2% (previous year: 13.4%).

The volatilities seen in our service part sales performance in the second half of 2012 in particular are no longer detectable to the same extent. In general, STRATEC's partners are still attempting to react flexibly to fluctuations in test volumes at their end customers by adjusting order volumes, even at short notice, to avoid building up stocks. In the first nine months of the current year, we witnessed slight volume growth in the service part business across virtually all of our customer base.

We boosted our overall workforce with a further seven employees in the past quarter to account in particular for the production of systems newly launched onto the market.

Three systems have already been launched onto the market by our partners bioMérieux, Bio-Rad and Quanterix over the past twelve months. These will increasingly contribute to STRATEC's positive sales performance. A further launch is scheduled to take place in the course of the fourth quarter.

Alongside a notable new development and supply agreement signed in the first quarter of 2013, the contract for a further major project is now in the final agreement stage. Both projects are expected to contribute to the positive development in the company's sales from 2015/2016.

The target published by STRATEC of generating sales of between €127 million and €138 million in the 2013 financial year, with an EBIT margin of 14.0% to 15.5%, is confirmed by the latest developments and by the orders and forecasts received from our partners.

Birkenfeld, October 2013

The Board of Management of

STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Bernd M. Steidle

INTERIM GROUP MANAGEMENT REPORT

REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

At the end of the first nine months of 2013, STRATEC can report year-on-year sales growth of 3.2% to €90.4 million. In the third quarter of 2013, the company achieved growth of 5.8% compared with the equivalent period in 2012. At €29.0 million (32.1 % of sales), gross profit fell slightly short of the previous year's figure.

Gross development expenses are €1.5 million up on the previous year's figure. Sales-related expenses, by contrast, fell year-on-year by €2.1 million. This was due to significantly lower market launch expenses. The slight increase in administration expenses mainly resulted from changes made to the compensation system.

The net balance of other operating expenses and income improved by €0.2 million, while the financial result deteriorated by €0.2 million. Depreciation and amortization amounted to €2.7 million, while investments in non-current assets totaled €3.4 million. EBIT amounted to €13.4 million, thus matching the previous year's figure. This corresponds to an EBIT margin of 14.8% (previous year: 15.3%). In the third quarter, the company generated an EBIT margin of 16.2% (previous year: 13.4%). The tax result amounted to €2.6 million. STRATEC can therefore report consolidated net income of €10.5 million for the period under report (previous year: €10.9 million). Earnings per share amounted to €0.90 (previous year: €0.93).

Inventories grew to €49.1 million, reflecting strong demand for analyzer systems and a fully stocked development pipeline. Receivables and other assets declined by €5.9 million, a development also reflected in the positive operating cash flow of €13.8 million. Cash and cash equivalents increased from €13.2 million to €18.7 million.

The equity ratio amounted to 75.3%. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Within other current liabilities, an amount of €8.9 million has been reported for prepayments received for development services.

CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

In its latest forecast, dated October 2013, the International Monetary Fund (IMF) sees the global economy growing more slowly than recently predicted. It therefore revised its growth forecast for the global economy downwards by 0.3 percentage points to 2.9%. This represents the fourth downward revision this year and the sixth consecutive downward revision. At 3.6%, growth in 2014 is also expected to be lower than previously thought. In July 2013, the IMF had still forecast 3.8%.

According to the IMF, growth is mainly being held back by high unemployment levels in Europe, uncertainty as to US monetary policy, and the faltering of emerging and developing economies, whose growth rates have had to be corrected significantly downwards.

For the euro area, the IMF now expects to see slightly more positive developments. The core European economies are showing some signs of recovery. As a result, economic output is now only expected to drop by 0.4% in 2013, rather than by the previously expected rate of contraction of 0.6%. In 2014, however, the euro area should show growth of almost 1%.

The IMF looks with some concern to the USA. Despite a recovery in demand in the real estate and financial sectors, the massive cuts in government budgets give the IMF reason to forecast weaker growth in the world's largest economy, namely of 1.6% in 2013 and 2.6% in 2014.

Irrespective of the aforementioned developments, global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications for STRATEC.

REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

The systems already established on the market have generated moderate growth rates. The systems launched onto the market in 2013 so far only account for an immaterial share of the current sales growth. We expect their share of sales to rise consistently over the coming quarters. Moreover, the market launch of a new system is due in the fourth quarter. Furthermore, two further market launches and analyzer system approvals are set to follow in 2014.

Alongside a major new development and supply agreement signed in the first quarter of 2013, a further contract is now in the final agreement stage. Both projects will make notable contributions to STRATEC's sales growth from the 2015 and 2016 financial years respectively.

On July 12, 2013, STRATEC reported the termination by a customer of a development and supply agreement. Compensation for STRATEC is being negotiated with the customer. At present, no more precise details can be provided as to the nature, amount or timing of such compensation. Neither the other projects with this partner nor projects with other partners have been affected by this contract termination.

Our ability to forecast developments continues to be impeded by several other external factors, such as capacity utilization rates at installed systems, the timing of further market launches, the planned production launches for new systems, further consolidation in the IVD market, and macroeconomic market factors.

The launch of mandatory health insurance cover by the Obama administration – so-called “Obamacare” – will benefit millions of previously uninsured American citizens, who will now gain regular access to healthcare services in what is already the world's largest healthcare market. Advocates of this healthcare reform are convinced that the millions of people additionally insured will curb the increase in healthcare costs in the USA and make medical care more cost-effective. Having said this, healthcare providers can expect to see greater pressure on prices due in particular to more widespread tendering by government bodies (tender business). STRATEC expects any additional pressure on prices to be compensated by rising test volumes and an additional increase in the degree of automation.

The current company forecast published on July 12, 2013 remains valid. Accordingly, STRATEC expects to generate sales of between €127 million and €138 million with an EBIT margin of 14.0% to 15.5% in the 2013 financial year. Average annual sales growth of 8% to 12% based on the figures for the 2013 financial year is then expected in subsequent years until 2017. Profitability is expected to improve slightly, albeit in proportion with the number and scale of new development projects and thus with the investments involved.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 26, 2013 upon the compilation of the Annual Report for the 2012 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

On July 12, 2013, STRATEC announced that the company had been informed by a customer that a contract for the development and supply of an analyzer system would no longer be continued due to a change in strategy on the part of the customer. Due to the discontinuation of this project, STRATEC thus stands to lose originally budgeted development and production sales in a double-digit euro range. In response to this event, STRATEC reduced its financial forecast on July 12, 2013. The termination of a contract by a customer at such an advanced stage of development – the analyzer system had almost reached the marketing stage – has never occurred previously in STRATEC's history and thus represents an one-off event. Although STRATEC views the risk of such an event reoccurring as extremely low, the possibility of such development cannot be entirely excluded. Strategic decisions by STRATEC's customers, which are mostly major groups with global operations in the in-vitro diagnostics industry, are difficult to predict and can mostly not be influenced by STRATEC.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development" and the comments concerning the customer contract termination in this "Opportunity and risk report", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2012 financial year dated March 26, 2013. Reference is made to the "Risk Report" section within the 2012 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

CONSOLIDATED BALANCE SHEET

as of September 30, 2013
of STRATEC Biomedical AG

ASSETS in € thousands	09.30.2013	12.31.2012
NON-CURRENT ASSETS		
Goodwill	4,476	4,547
Other intangible assets	6,962	6,192
Property, plant and equipment	17,115	17,108
Interests in associates	391	363
Deferred tax assets	1,447	1,260
	30,391	29,470
CURRENT ASSETS		
Raw materials and supplies	9,524	8,857
Unfinished products, unfinished services	38,720	34,406
Finished products, goods and prepayments	897	807
Trade receivables	18,076	23,802
Future receivables from construction contracts	6,230	6,627
Receivables from associates	57	96
Income tax receivables	1,952	2,016
Other receivables and other assets	2,256	2,182
Other financial assets	529	366
Cash and cash equivalents	18,709	13,209
	96,950	92,368
TOTAL ASSETS	127,341	121,838

SHAREHOLDERS' EQUITY AND DEBT in € thousands	09.30.2013	12.31.2012
SHAREHOLDERS' EQUITY		
Share capital	11,748	11,738
Capital reserve	16,568	16,247
Revenue reserves	56,458	48,966
Consolidated net income	10,517	13,973
Other equity	583	1,061
	95,874	91,985
DEBT		
Non-current debt		
Non-current financial liabilities	6,948	7,459
Pension provisions	28	28
Deferred taxes	2,108	2,060
	9,084	9,547
Current debt		
Current financial liabilities	1,736	1,183
Trade payables	6,035	4,288
Liabilities to associates	204	282
Other current liabilities	13,245	13,707
Current provisions	607	608
Income tax liabilities	556	238
	22,383	20,306
TOTAL SHAREHOLDERS' EQUITY AND DEBT	127,341	121,838

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from July 1 to September 30, 2013
of STRATEC Biomedical AG

in € thousands	07.01. - 09.30.2013	07.01. - 09.30.2012
Sales	31,037	29,342
Cost of sales	-21,629	-20,323
Gross profit	9,408	9,019
Research and development expenses	-1,169	-569
Information only: Total research and development expenses	-4,746	-3,676
Information only: Capitalized research and development expenses	3,577	3,107
Sales-related expenses	-998	-2,468
General administrative expenses	-2,007	-1,755
Other operating income and expenses	-219	-294
EBIT	5,015	3,933
Net financial expenses	-42	99
Earnings before taxes (EBT)	4,973	4,032
Current tax expenses	-1,043	-570
Deferred tax expenses (previous year: tax income)	-192	51
Consolidated net income	3,738	3,513
Income and expenses recognized directly in equity (after taxes)		
Hedge transactions	0	54
Currency translation of foreign financial statements	-40	28
Comprehensive income	3,698	3,595
Earnings per share in €		
	0.32	0.30
No. of shares used as basis	11,735,522	11,701,548
Earnings per share, diluted, in €		
	0.32	0.30
No. of shares used as basis, diluted	11,745,192	11,737,403

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to September 30, 2013
of STRATEC Biomedical AG

in € thousands	01.01. - 09.30.2013	01.01. - 09.30.2012
Sales	90,418	87,584
Cost of sales	-61,422	-58,103
Gross profit	28,996	29,481
Research and development expenses	-3,179	-1,872
Information only: Total research and development expenses	-14,691	-13,150
Information only: Capitalized research and development expenses	11,512	11,278
Sales-related expenses	-5,268	-7,333
General administrative expenses	-6,679	-6,239
Other operating income and expenses	-509	-680
EBIT	13,361	13,357
Net financial expenses	-251	-28
Earnings before taxes (EBT)	13,110	13,329
Current tax expenses	-2,719	-3,178
Deferred tax income	126	714
Consolidated net income	10,517	10,865
Income and expenses recognized directly in equity (after taxes)		
Hedge transactions	0	-28
Currency translation of foreign financial statements	-478	190
Comprehensive income	10,039	11,027
Earnings per share in €		
	0.90	0.93
No. of shares used as basis	11,729,395	11,679,231
Earnings per share, diluted, in €		
	0.90	0.93
No. of shares used as basis, diluted	11,760,492	11,738,467

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the Period from January 1 to September 30, 2013
of STRATEC Biomedical AG

JANUARY - SEPTEMBER 2012

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
Balance at 01.01.2012	11,675	15,307	26,706	13,392
Equity transactions with owners				
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	61	759		
Allocations due to stock option plans		100		
Value changes recognized directly in equity				
Allocation to free revenue reserves				3,000
Profit carried forward			5,867	
Consolidated net income				
Balance at 09.30.2012	11,736	16,166	32,573	16,392

JANUARY - SEPTEMBER 2013

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
Balance at 01.01.2013	11,738	16,247	32,574	16,392
Equity transactions with owners				
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	10	184		
Allocations due to stock option plans		133		
Value changes recognized directly in equity				
Allocation to free revenue reserves				3,000
Profit carried forward			4,406	
Change in scope of consolidation		4		86
Consolidated net income				
Balance at 09.30.2013	11,748	16,568	36,980	19,478

	Free revenue reserves	Other equity			Group equity
		Treasury stock	Currency translation	Hedge transactions	
	15,282	-212	1,082	0	83,232
	-6,415				-6,415
					820
					100
			190	-28	162
	-3,000				0
	-5,867				0
	10,865				10,865
	10,865	-212	1,272	-28	88,764

Consolidated net income	Other equity		Group equity
	Treasury stock	Currency translation	
13,973	-212	1,273	91,985
-6,567			-6,567
			194
			133
		-478	-478
-3,000			0
-4,406			0
			90
10,517			10,517
10,517	-212	795	95,874

CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to September 30, 2013
of STRATEC Biomedical AG

in € thousands	01.01. – 09.30.2013	01.01. – 09.30.2012
Consolidated net income (after taxes)	10,517	10,865
Depreciation and amortization	2,697	2,976
Current income tax expenses	2,719	3,178
Income taxes paid less income taxes received	-1,941	-4,492
Financial income	-54	-174
Financial expenses	305	206
Interest paid	-281	-158
Interest received	70	156
Other non-cash expenses	488	222
Other non-cash income	-2,340	-1,873
Cash flow	12,180	10,906
Change in deferred taxes through profit or loss	-126	-714
Profit on disposals of non-current assets	-9	-21
Decrease (previous year: increase) in inventories, trade receivables, and other assets	311	-11,481
Increase in trade payables and other liabilities	1,424	3,314
Inflow of funds from operating activities	13,780	2,004
Incoming payments from disposals of non-current assets		
Property, plant and equipment	9	50
Outgoing payments for investments in non-current assets		
Intangible assets	-333	-204
Property, plant and equipment	-1,260	-1,140
Financial assets	-100	-30
Outflow of funds for investing activities	-1,684	-1,324
Incoming payments from taking up of financial liabilities	1,000	77
Outgoing payments for repayment of financial liabilities	-932	-612
Incoming payments for issues of shares for employee stock option programs	194	820
Dividend payment	-6,567	-6,415
Outflow of funds for financing activities	-6,305	-6,130
Cash-effective change in cash and cash equivalents	5,791	-5,450
Cash and cash equivalents at start of period	13,209	19,548
Change in scope of consolidation	84	0
Impact of exchange rate movements	-375	27
Cash and cash equivalents at end of period	18,709	14,125

NOTES TO THE GROUP INTERIM REPORT

for the Period from January 1 to September 30, 2013
of STRATEC Biomedical AG

Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2012 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of September 30, 2013, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2012 financial year. Exceptions relate to the first-time full consolidation of STRATEC Biomedical S.R.L., Romania, which was founded in the 2008 financial year, the merger of STRATEC Molecular GmbH, Germany*, with STRATEC NewGen GmbH, Germany*, and the foundation of STRATEC Biomedical (Taicang) Co., Ltd., China*. The implications for the net asset, financial and earnings position of the STRATEC Group are still of subordinate significance.

Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of September 30, 2013.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2012 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

* Included in the consolidated financial statements as of December 31, 2012 by way of full consolidation respectively due to subordinate significance included in the consolidated financial statements as of September 30, 2013 at cost.

Segment disclosures

Apart from the first-time inclusion of STRATEC Biomedical S.R.L., Romania, in the “Instrumentation” segment, there have been no changes in segmentation compared with the consolidated financial statements as of December 31, 2012.

Segment data by operating segment for the period from January 1 to September 30, 2013

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	93,396	3,481	-6,459	90,418
EBIT	14,352	-504	-487	13,361
Assets	145,278	4,300	-22,237	127,341

Segment data by operating segment for the period from January 1 to September 30, 2012

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	91,631	2,978	-7,025	87,584
EBIT	15,250	-1,384	-509	13,357
Assets	133,910	3,613	-18,369	119,154

The breakdown of sales by geographical region represents the distribution of the STRATEC Group’s products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group’s analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - September 2013	15,059	36,551	38,808	90,418
	16.7 %	42.9 %	40.4 %	100.0 %

in € thousands	Germany	EU	Other	Total
January - September 2012	12,560	38,954	36,070	87,584
	14.3 %	44.5 %	41.2 %	100.0 %

Research and development expenses

Research and development expenses not fulfilling the capitalization criteria set out in IAS 38 (Intangible Assets) amounted to €3.2 million in the first nine months of the 2013 financial year (previous year: €1.9 million) and mainly involve personnel and material expenses. The STRATEC Group invested a total of €14.7 million in research and development in the first nine months of the 2013 financial year (previous year: €13.2 million).

Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 13 and 14.

The number of ordinary shares with a nominal value of €1.00 each issued by STRATEC Biomedical AG as of September 30, 2013 amounts to 11,747,745. These are all bearer shares.

Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC Biomedical AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of €12,223.00 of the company's share capital and to a 0.10% share of its equity.

Stock option programs

Members of the Board of Management/Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	Board of Management/ Managing Directors	Employees	Total
Outstanding on 01.01.2013	123,000	64,200	187,200
Issued	50,000	34,550	84,550
Exercised	0	10,000	10,000
Lapsed	0	1,400	1,400
Forfeited	2,000	2,000	4,000
Outstanding on 09.30.2013	171,000	85,350	256,350

Of the stock option rights granted in the first nine months, 50,000 were granted to members of the Board of Management (previous year: 60,000), 0 to managing directors of subsidiaries (previous year: 0), and 34,550 to employees (previous year: 7,050).

Furthermore, members of the Board of Management exercised 0 stock option rights in the first nine months (previous year: 55,000), while managing directors of subsidiaries also exercised 0 stock option rights in this period (previous year: 0). Employees exercised 10,000 stock option rights (previous year: 5,750). To service the stock option rights exercised, a total of 10,000 shares were created from conditional capital (previous year: 60,750).

A total of 1,400 stock option rights for employees lapsed in the period under report (previous year: 200).

Furthermore, 2,000 stock option rights were forfeited for each of the managing director and employee categories (previous year: 0 each).

Employees

Including temporary employees, the STRATEC Group had a total workforce of 544 employees as of September 30, 2013 (previous year: 524).

Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

ADDITIONAL INFORMATION

FINANCIAL CALENDAR

November 12, 2013 German Equity Forum, Frankfurt/Main, Germany
- Analysts' conference -

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2013:

November 2013 5th LBBW German Company Day, London, UK
Jefferies 2013 Global Healthcare Conference, London, UK
7th HSBC Healthcare Day, Frankfurt/Main, Germany
Bryan, Garnier & Co Conference, Paris, France

December 2013 10th Annual Berenberg European Conference, Pennyhill Park, UK

Partially incomplete/subject to amendment

ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at www.stratec.com.

IMPRINT

Published by

STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0
Fax: +49 7082 7916-999
info@stratec.com
www.stratec.com

Investor Relations

ANDREAS KÜNZEL
Phone: +49 7082 7916-185
Fax: +49 7082 7916-999
a.kuenzel@stratec.com

ANDRE LOY
Phone: +49 7082 7916-190
Fax: +49 7082 7916-999
a.loy@stratec.com

NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

STRATEC BIOMEDICAL AG

Gewerbestr, 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

info@stratec.com

www.stratec.com